Johnson & Johnson has announced Week 48 results from the Phase 3 FUZION trial of TREMFYA (guselkumab) in adults with Crohn’s disease and perianal fistula. Combined fistula remis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results